Enabling Advances & Technologies

We are building this Page  !

Mass Spectrometry 

                                           Peaks of Prague  - Entwined in our logo

All aspects of Mass Spectrometry (details to be added)

• Fundamentals of Mass Spectrometry

• Proteomics

• Chromatography

• Hyphenated separation techniques

• Bio separation techniques

• Membrane science and technology

• Application of separation techniques  

• Spectroscopy as separation techniques

• Advances in Chromatography and Mass Spectrometry

• Spectroscopy

• Mass Spectrometry in Metabolomics and Lipidomics

• Nuclear Magnetic Resonance (NMR) Spectroscopy

• Clinical application of mass spectrometry

• UV, IR and Ion Spectroscopy

• Bioinformatics and Computational Biology

• Proteins Biochemistry

• Electrophoresis

• Forensic Science

• Membrane Techniques

• Separation Techniques Based on Rate Phenomena

• Mass spectrometry in environmental analysis

• Digital Proteomics with intelligence driven quatitative Mass Spectrometry 

Protein Printing and AI

Protein Printing platform can create a new approach for drug discovery and cell line development for next-generation biologics. Such platforms may help to design proteins by predicting not only the optimal sequence for each therapeutic candidate, but also the conditions for manufacturing to enable production of therapeutic proteins that were previously not possible. Such a technology combined with AI (artificial intelligence engines) capable of interpreting disparate biological data types to answer biology’s toughest questions, may be the ideal combination for therapeutics that have proved challenging. Incorporating deep learning can help explore all possible protein sequences in silico, including those that Nature’s evolutionary trajectory has yet to consider as well as to identify drug candidates with optimal therapeutic properties.

Expression system such as E. coli expression system, combined with Protein Printing platform, may enable simultaneous creation of novel biotherapeutic drugs and the cell lines to manufacture them in a single efficient process. A single workflow may select cell lines producing drug candidates with optimal target potency and affinity as well as high-titer expression. Starting with a known drug sequence or with a target for novel drug discovery and complex protein scaffolds, such an approach may dramatically reduce timelines. 

Protein imaging 

Other enabling technologies

Bioinformatics  

Stem Cells

Antibodies

Biomarkers 

Diseases  Drugs

Genome editing and the Nobel Prize 2020

The use of CRISPR/Cas9 genetic scissors, has not only revolutionised basic science, but will lead to ground-breaking new medical treatments.  There is enormous power in this genetic tool which can change the code of life !        

In medicine, clinical trials of new cancer therapies are underway, and the dream of being able to cure inherited diseases is about to come true. These genetic scissors have taken the life sciences into a new era and, in many ways, bringing great benefit to humankind.

                                       Gene Editing   <    CLICK TO READ 

Challenges:

Developing CRISPR cell and gene therapies is a complex and daunting task and gene therapy field is predicted to expand even more rapidly over the coming years, with researchers across the globe working to generate curative treatments for a significant number of the >5,000 known monogenic disorders. In order to ensure CRISPR therapies are safe, effective, and available to patients, it’s imperative that we find solutions to the problems faced by researchers.

Recent advances:

Genome editing and CRISPR technology are on the rise.  In February 2022, CRISPR Therapeutics and ViaCyte made history, carrying out the first-in-human transplant of gene-edited, stem cell-derived pancreatic cells to treat Type 1 diabetes (T1D). With results of an animal study published in February 2023, Genprex aims to add credibility to another genome editing approach in the hunt for a functional cure to T1D. While traditional gene therapies include replacement gene therapy, gene editing and CAR-T for diabetes, Genprex aims to use Adeno-Associated Virus (AAV) pancreatic intraductal infusions to deliver Pdx1 and MafA genes to the pancreas.